Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
11203 résultats correspondants
· 42 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 6229
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| CD19 t-haNK NCT07556757 · A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lympho… | Sclérose en plaques | À vérifier | Phase 1 | TERMINATED | This is a phase 1, open-label study to evaluate the safety and efficacy of… À vérifier | ClinicalTrials.gov 2026-11-22 04:39:02 | Détail |
| Chimeric Antigen Receptor T-Cell Therapy NCT05052528 · Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | SUSPENDED | This phase II trial tests how well odronextamab works before and after sta… À vérifier | ClinicalTrials.gov 2026-11-22 04:39:02 | Détail |
| QT-019C NCT07416032 · A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal All… | Sclérose en plaques | Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier | ClinicalTrials.gov 2026-11-22 04:39:02 | Détail |
| Glofitamab NCT05798156 · R-Pola-Glo — Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in… | Sclérose en plaques | À vérifier | Phase 2 | ACTIVE_NOT_RECRUITING | This Phase II trial evaluates the optimization of the cytokine release syn… À vérifier | ClinicalTrials.gov 2026-11-22 04:39:01 | Détail |
| Rituximab NCT04914741 · COALITION — A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Po… | Sclérose en plaques | Immunomodulation | Phase 1/2 | UNKNOWN | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-11-22 04:39:01 | Détail |
| TQB2303 NCT03456466 · Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma | Sclérose en plaques | Immunomodulation | Phase 1/2 | UNKNOWN | Primary Outcome Measures: Area under the curve (AUC) forTQB2303 and rituxi… À vérifier | ClinicalTrials.gov 2026-11-22 04:39:01 | Détail |
| Plerixafor NCT03406091 · Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients | Sclérose en plaques | Thérapie cellulaire | À vérifier | COMPLETED | The purpose of this study is to determine whether it is safe and effective… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:57 | Détail |
| Aminophylline NCT07617896 · Intravesical Aminophylline to Facilitate Ureteroscopic Access in Children With D… | Sclérose en plaques | À vérifier | Phase 2 | RECRUITING | This safety study is the first in a series of studies testing the applicat… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:56 | Détail |
| Theophylline NCT07515456 · Theophylline, Versus Sumatriptan and Gabapentin in The Treatment of Post-Dural P… | Sclérose en plaques | À vérifier | Non applicable | RECRUITING | To evaluate the effect of multiple doses of BIIL 284 BS on the pharmacokin… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:56 | Détail |
| AND017 NCT07487727 · A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to… | Maladie rénale chronique | À vérifier | Phase 3 | RECRUITING | This is a Phase III, randomized, open-label, active-controlled study to ev… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:40 | Détail |
| AND017 capsules NCT07950215 · A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associate… | Maladie rénale chronique | À vérifier | Phase 3 | NOT_YET_RECRUITING | This is a Phase 3, randomized, open-label, active-controlled study to eval… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:40 | Détail |
| AND017 capsules NCT07494409 · A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic… | Maladie rénale chronique | À vérifier | Phase 3 | ACTIVE_NOT_RECRUITING | This is a Phase 3, randomized, open-label, active-controlled study to eval… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:40 | Détail |
| AP306 75 mg BID NCT06712654 · A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in… | Maladie rénale chronique | À vérifier | Phase 2 | ACTIVE_NOT_RECRUITING | This study is being conducted to characterize the safety, tolerability, an… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:40 | Détail |
| Arm 1: SOC (mTOR + CNI) NCT06552169 · RETIRE — REgulatory T Cell Therapy to Achieve Immunosuppression REduction | Maladie rénale chronique | Immunomodulation · Thérapie cellulaire | Phase 2 | RECRUITING | The goal of this multi-national, multi-center, open-label, randomized Phas… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:40 | Détail |
| Chlorhydric acid based acid concentrate for bicarbonate hemodialysis… NCT04824885 · Study of a Dialysate Without Acetate on Protein Energy Wasting Syndrome in Chron… | Maladie rénale chronique | À vérifier | Non applicable | COMPLETED | This work aims to study the effect of an acetate-free dialysate on protein… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:40 | Détail |
| colchicine NCT04500665 · Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine | Maladie rénale chronique | Immunomodulation | Phase 2 | TERMINATED | Colchicine is a supressor of hepatic CYP1A2 and theophylline is a sensitiv… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:40 | Détail |
| Empagliflozin NCT06013865 · SEKTR — Empagliflozin Treatment in Kidney Transplant Recipients | Maladie rénale chronique | À vérifier | Phase 4 | RECRUITING | The purpose of this study is to find out what effects (good and bad) the s… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:40 | Détail |
| Etelcalcetide NCT03969329 · A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism… | Maladie rénale chronique | À vérifier | Phase 3 | RECRUITING | Assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (P… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:40 | Détail |
| Ferrous Sulfate NCT03991169 · FeTCh-CKD — Oral Iron in Children With Chronic Kidney Disease | Maladie rénale chronique | À vérifier | Phase 4 | COMPLETED | This is a Phase 1b, randomized, double-blinded, placebo-controlled study o… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:40 | Détail |
| Moda-flx Hemodialysis System™ NCT06613568 · Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Indivi… | Maladie rénale chronique | À vérifier | Non applicable | RECRUITING | The purpose of this study is to evaluate the safety and efficacy of the Mo… À vérifier | ClinicalTrials.gov 2026-11-22 04:38:40 | Détail |
Découverte scientifique
Recherches et trouvailles 22
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Thonningianin A Thonningianin A — neuroprotection anti-amyloïde | Maladie d’Alzheimer | Neuroprotection | Validation animale | Préliminaire | Modulation du stress oxydatif et des protéines associées à Alzheimer · Voi… Candidat naturel étudié dans des systèmes précliniques pour ses effets neuroprotecteurs face à plusieurs mécanismes ass… | Publication évaluée par les pairs 2024-09-01 | Détail |
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4952
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| CBCT based online daily adaptive treatment improves target coverage w… radiation therapy · PMID 42415083 | Cancer | Traitement symptomatique | Publication | PubMed | Voir la publication source The precise application of stereotactic body radiation therapy (SBRT) for prostate cancer is challenged by prostate mot… | Radiation oncology (London, England) 2026-07-08 12:06:45 | Source |
| Comparative outcomes of proton and photon therapy in the management o… radiation therapy · PMID 42414660 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Malignant Peripheral Nerve Sheath Tumors (MPNSTs) are aggressive sarcomas often arising in the spine, characterized by… | European spine journal : official publication of the E… 2026-07-08 12:06:45 | Source |
| Association Between Geriatric Nutritional Risk Index and Gemcitabine… paclitaxel albumin-stabilized nanoparticle formulation · PMID 42373239 | Cancer | À vérifier | Publication | PubMed | Voir la publication source This retrospective study evaluated the impact of Geriatric Nutritional Risk Index (GNRI) group on time to treatment fai… | Anticancer research 2026-07-08 12:06:44 | Source |
| Nab-paclitaxel or Paclitaxel Treatment for Relapsed Small Cell Lung C… paclitaxel albumin-stabilized nanoparticle formulation · PMID 42373285 | Cancer | Ralentissement de la progression | Publication | PubMed | Voir la publication source Relapsed small cell lung cancer (SCLC) treatment has limited evidence-based options. Solvent-based paclitaxel (PTX) and… | Anticancer research 2026-07-08 12:06:44 | Source |
| Responsive stimulation of the thalamus for idiopathic generalized epi… RNS® System · PMID 42233958 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source This study was undertaken to evaluate the safety and effectiveness of responsive thalamic stimulation as adjunctive the… | Epilepsia 2026-07-08 12:06:44 | Source |
| Thalamocortical seizure onset patterns in drug-resistant focal epilep… RNS® System · PMID 42396599 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source Drug-resistant epilepsy affects tens of millions of people worldwide and is associated with considerable morbidity and… | Brain communications 2026-07-08 12:06:44 | Source |
| A review of the efficacy and safety of eslicarbazepine acetate in the… BIA 2-093 · PMID 26136845 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source Eslicarbazepine acetate is a is a once-daily antiepileptic drug (AED) that was approved in 2009 by the European Medicin… | Therapeutic advances in neurological disorders 2026-07-08 12:06:42 | Source |
| K7 and K Potassium Channels in Thalamocortical Function and Their The… Effects of Antiepileptic Drugs on Brain Excitability · PMID 42261627 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source Potassium (K) channels are one of the key regulators of neuronal excitability and network stability. Among all the pota… | Archiv der Pharmazie 2026-07-08 12:06:42 | Source |
| Lateral Habenula 5-HT₂A Receptors Mediate Social Deficits in a Valpro… Effects of Antiepileptic Drugs on Brain Excitability · PMID 42277370 | Épilepsie | Traitement symptomatique | Publication | PubMed | Voir la publication source Autism Spectrum Disorder (ASD) is characterized by social deficits, yet underlying neural mechanisms remain poorly unde… | Molecular neurobiology 2026-07-08 12:06:42 | Source |
| Progress report on new antiepileptic drugs: a summary of the Ninth Ei… BIA 2-093 · PMID 19008076 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source The Ninth Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT IX, took place in Sitges, Barcelona from the 15th to… | Epilepsy research 2026-07-08 12:06:42 | Source |
| Diagnostic performance of [18F]FDG PET/CT in large vessel vasculitis… 18F-FDG · PMID 42411928 | Cancer · Épilepsie · Épilepsie | Immunomodulation | Publication | PubMed | Voir la publication source Large vessel vasculitis (LVV), encompassing giant cell arteritis (GCA), Takayasu arteritis (TAK) and polymyalgia rheuma… | The quarterly journal of nuclear medicine and molecula… 2026-07-08 12:06:41 | Source |
| Divergent Radiomolecular Phenotype of Spindle Cell Lipoma: Inten… 18F-FDG · PMID 42411770 | Cancer | À vérifier | Publication | PubMed | Voir la publication source A 68-year-old man with gastric cancer underwent 18F-fluorodeoxyglucose (FDG) PET/CT, which revealed an incidental subcu… | Clinical nuclear medicine 2026-07-08 12:06:41 | Source |
| Intermittent theta burst stimulation enhances the efficacy of brain-c… Intermittent theta burst stimulation · PMID 42404120 | Accident vasculaire cérébral | À vérifier | Publication | PubMed | Voir la publication source "BCI illiteracy," characterized by insufficient -rhythm Event-Related Desynchronization (ERD) in approximately 40% of s… | Frontiers in neurology 2026-07-08 12:06:40 | Source |
| Subchronic comparative assessment of graded ferrous sulfate doses on… 0.9% NaCl · PMID 42376110 | Maladie d’Alzheimer | Neuroprotection · Immunomodulation | Publication | PubMed | Voir la publication source Iron is a necessary trace element in the human body. However, excessive concentration can promote the overproduction of… | Open veterinary journal 2026-07-08 12:06:39 | Source |
| Sustainable soil improvement strategies for coral islands: Synergisti… 0.9% NaCl · PMID 42379437 | Maladie d’Alzheimer | À vérifier | Publication | PubMed | Voir la publication source The sustainable development of coral islands is constrained by bottleneck issues such as poor water retention and nutri… | International journal of biological macromolecules 2026-07-08 12:06:39 | Source |
| Minaxolone: an evaluation with and without premedication. Allopregnanolone injection (intravenous solution) · PMID 7270828 | Maladie d’Alzheimer | Traitement symptomatique | Publication | PubMed | Voir la publication source Minaxolone, a water-soluble steroid intravenous anaesthetic, has been used in clinical trials for induction and mainten… | Anaesthesia 2026-07-08 12:06:38 | Source |
| Continuous theta burst stimulation to the frontal pole durably decrea… Continuous theta burst stimulation · PMID 42379239 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source The frontal pole is a transdiagnostic target for affective disorders, perhaps through its connectivity with affective r… | International review of psychiatry (Abingdon, England) 2026-07-08 12:06:37 | Source |
| Role of the Upper Motor Neuron in the Generation of Fasciculations in… Continuous theta burst stimulation · PMID 42407013 | Sclérose latérale amyotrophique | À vérifier | Publication | PubMed | Voir la publication source The origin of fasciculation potentials (FPs) in the early stages of amyotrophic lateral sclerosis (ALS) remains a subje… | Neurology 2026-07-08 12:06:37 | Source |
| Extrapontine Myelinolysis and Reversible Parkinsonism After Hyponatre… Levodopa/carbidopa solution for SC administration · PMID 30055367 | Maladie de Parkinson | Traitement symptomatique | Publication | PubMed | Voir la publication source Osmotic demyelination syndrome commonly follows rapid correction of hyponatremia. Although pons is a common location, e… | World neurosurgery 2026-07-08 12:06:36 | Source |
| Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson'… Levodopa/carbidopa solution for SC administration · PMID 33772855 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source The aim was to demonstrate that continuous s.c. infusion of a soluble levodopa (LD)/carbidopa (CD) phosphate prodrug co… | Annals of neurology 2026-07-08 12:06:36 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||